ORIC earnings analysis
What we found in ORIC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
ORIC is a clinical-stage, pre-revenue oncology company whose Q2 loss widened to $41.5 million from $36.4 million as R&D spending increased 19% year over year to $36.3 million, principally to advance rinzimetostat. The key positive is execution progress: Himalayas-1, its first global Phase 3 registrational trial, began in July, while enozertinib data are expected in 2H 2026. Liquidity is substantial at $387.6 million and is expected to support operations into 2H 2028, but the investment case remains dependent on clinical readouts, Phase 3 execution, continued financing and rising development costs.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Rinzimetostat entered global Phase 3
- ORIC initiated the global registrational Himalayas-1 Phase 3 trial of rinzimetostat plus darolutamide in July 2026. The recommended Phase 3 regimen was supported by a 84% landmark 5-month rPFS rate in March 2026 data.
- Cash runway extends into 2H 2028
- Cash, cash equivalents and investments totaled $387.6 million at June 30, 2026. Management expects this capital to fund the current operating plan into the second half of 2028.
- Per-share loss improved year over year
- The quarterly diluted EPS loss improved to $0.38 from a $0.47 loss in Q2 2025, despite the reported net loss increasing to $41.5 million from $36.4 million due to a higher share count.
- Investment focused on lead Phase 3 asset
- Rinzimetostat external R&D spending rose $8.6 million year over year to $16.0 million in Q2, reflecting advancement of the program. Bayer will provide darolutamide at no cost for the Himalayas-1 study.
- ATM financing reinforced liquidity
- ORIC raised approximately $59.9 million net through ATM sales of 4,698,400 shares during the first half of 2026, at a weighted-average price of $12.96 per share.
- Enozertinib data catalyst expected in 2H26
- Management expects to report enozertinib data in 2H 2026 across first-line EGFR exon 20 insertion NSCLC monotherapy and SC amivantamab combination cohorts, plus first-line EGFR atypical mutation monotherapy.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Losses widened and no product revenue
- ORIC remains pre-revenue and reported a $41.5 million Q2 net loss, up $5.1 million from $36.4 million a year earlier; the six-month loss rose to $77.3 million from $66.4 million. Accumulated deficit reached $769.5 million at June 30, 2026.
- Phase 3 spending raises cash-burn risk
- R&D expense increased $5.7 million year over year to $36.3 million in Q2, led by an $8.6 million increase in rinzimetostat external costs. Management expects losses to increase significantly as its two lead programs advance, particularly into larger later-stage trials.
- China supply and tariff exposure
- A new supply-chain and trade-policy exposure is more material because ORIC uses Chinese manufacturers for APIs and reported Chinese-origin goods tariffs of 30%, alongside a 10% reciprocal baseline tariff on certain products from most other trading partners. Additional pharmaceutical tariffs remain under investigation.
- BIOSECURE Act may constrain vendors
- The filing adds material execution risk from the new BIOSECURE Act: implementing regulations are expected by approximately mid-2028, while ORIC currently contracts with Chinese companies for certain R&D services. A designation of a provider as a biotechnology company of concern could constrain services or affect partner perceptions.
- AI gap and data-security exposure
- The risk discussion was expanded for AI adoption: ORIC states its current AI-platform use is relatively minimal, while competitors may gain an advantage through AI-enabled development. AI use could also create confidentiality, cybersecurity, IP and regulatory risks.
- Ongoing financing and dilution requirement
- Operating cash use was $64.0 million in the first six months of 2026, versus $63.4 million a year earlier, while no capex figure was disclosed to calculate free cash flow. The company will require substantial additional capital beyond its stated runway and has a remaining ATM capacity of up to $200.0 million.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.38
What they said about what is next.
No revenue or EPS guidance was provided. Management expects $387.6 million of cash, cash equivalents and investments as of June 30, 2026 to fund its operating plan into the second half of 2028, and expects enozertinib data in the second half of 2026.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 4, 2026
- ORIC Pharmaceuticals reported no revenue for Q1 2026, reflecting continued investment in R&D which rose to $31.4M, up from $24.6M year-over-year, amidst a net loss of $35.8M compared to $30.0M in the prior year. Despite…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ORIC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever